Neurological Institute Outcomes
Surgical Quality Improvement
Brain Tumor Surgery Outcomes
Brain Tumor Surgery ACS NSQIP Outcomes
January 1, 2020 – December 31, 2020
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s overall brain tumor surgery ACS NSQIP performance benchmarked against 226 participating sites.
|Brain Tumor (226 Sites)||N||Observed||Expected|
|30 Day Mortality||238||1.26%||1.87%|
|30 Day Morbidity||238||12.61%||10.33%|
|Ventilator > 48 Hours||238||2.52%||1.66%|
|Deep Vein Thrombosis (DVT) / Pulmonary Embolus||238||4.20%||3.92%|
|Urinary Tract Infection (UTI)||238||1.68%||1.32%|
|Surgical Site Infection (SSI)||238||3.78%||2.08%|
|Return to Operating Room (ROR)||238||5.04%||5.24%|
American College of Surgeons National Surgical Quality Improvement Program, 2021.
ACS NSQIP® Semiannual Report July 8, 2021, Chicago: American College of Surgeons.
ᵃIdentified as a statistical outlier (higher than expected) by the ACS NSQIP hierarchical model.